SFCC Sfbc (MM)

SFBC International, Inc. (NASDAQ: SFCC), a provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today provided details on the composition of its Board of Directors. Due to recent resignations, changes were made to the Board of Directors, which Nasdaq recently confirmed are compliant with Nasdaq Marketplace Rules. SFBC International stated that it is currently in compliance with Nasdaq Marketplace Rules 4350 (c)(1) and 4350(d)(2), but it was not in compliance for a limited period of time as a result of the resignation of Dr. Leonard Weinstein on December 15, 2005. Under Rule 4350(c), SFBC had until the earlier of its next annual shareholders' meeting or December 15, 2006 to appoint an additional independent director and thereby regain compliance. On January 13, 2006, Nasdaq provided SFBC with notice of the prior non-compliance with Marketplace Rules 4350(c)(1) and 4350(d)(2). This release is being issued in accordance with Marketplace Rule 4803(a). The company regained compliance with the appointment of Mr. David Lucking to the Audit Committee on December 21, 2005, and upon the resignations of Dr. Lisa Krinsky and Mr. Arnold Hantman, which were effective on December 31, 2005. Nasdaq Marketplace Rules 4350 (c)(1) and 4350(d)(2) require that a majority of the Board be comprised of independent directors and that the Audit Committee be comprised of three independent directors, including at least one member who has financial sophistication. As of December 31, 2005, a majority of the Company's Board of Directors was comprised of independent directors as required by Nasdaq Marketplace Rule 4350(c)(1). In addition, as required by Nasdaq Marketplace Rule 4350(d)(2), the Audit Committee is currently comprised of three independent directors, and Mr. Jack Levine, Chairman, and Mr. Arnold Goleib each satisfy the Audit Committee Financial Expert requirement of Securities and Exchange Commission Rules, which satisfies the Nasdaq financial sophistication requirement. About SFBC International, Inc. SFBC International, Inc. provides early and late stage clinical drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies around the world. SFBC has more than 30 offices located in North America, Europe (including Central and Eastern Europe), South America, Asia, and Australia. In early clinical development services, SFBC specializes primarily in the areas of Phase I and early Phase II clinical trials and bioanalytical laboratory services, including early clinical pharmacology. SFBC also provides late stage clinical development services globally that focus on Phase II through IV clinical trials. SFBC also offers a range of complementary services, including data management and biostatistics, central laboratory services, medical and scientific affairs, regulatory affairs and submissions, and clinical IT solutions. Additional information is available on SFBC's website at www.sfbci.com.